Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 14 at 2:00 PM ET

Register Free →
← Back to NAICS Codes
NAICS Code· 325414

NAICS 325414: Biological Product (except Diagnostic) Manufacturing

This U.S. industry comprises establishments primarily engaged in manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic). Cross-References. Establishments primarily engaged in--Show more

NAICS 325414 – Biological Product (except Diagnostic) Manufacturing encompasses the production of therapeutic and prophylactic biological substances intended for human or veterinary use, excluding diagnostic agents. This includes vaccines, blood derivatives, recombinant proteins, monoclonal antibodies, gene therapies, and other biologics derived from living organisms.

14
Active Contracts
$122.2M
Total Obligations (12mo)
175
Awarded Contracts (12mo)
81
Contractors Awarded (12mo)
1
Median Bidders per Award
-73.6%
YoY Growth
Dotted
NAICS 325414 FAQ

Frequently Asked Questions

NAICS code 325414 covers Biological Product (except Diagnostic) Manufacturing. This U.S. industry comprises establishments primarily engaged in manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic). Cross-References. Establishments primarily engaged in--

Recently Posted in Biological Product (except Diagnostic) Manufacturing

NAICS: 325414
DIBBS
JAPANESE ENCEPHALIT
Solicitation # SPE2DP-26-R-0001
The Defense Logistics Agency Troop Support is soliciting Japanese Encephalitis Virus Vaccine, Purified, Inactivated, Single-Dose Prefilled Syringes under solicitation SPE2DP-26-R-0001, with a sole source justification under FAR 6.302-1 due to the unique nature of the product and regulatory requirements. The acquisition will follow Part 12 procedures for commercial items, resulting in a firm-fixed-price, indefinite delivery, indefinite quantity contract with an 18-month base term. The minimum order is 277,760 units, with an estimated and maximum quantity of 277,760 and 394,240 units respectively. Vaccines must be FDA-approved prior to the solicitation’s closing date and must comply with MPID Number 5 dated July 23, 2024. All deliveries are FOB destination to DLA Distribution Susquehanna in New Cumberland, Pennsylvania, with a 120-day production lead time following issuance of each DD1155 delivery order. Inspection and acceptance occur at the delivery point, and the contractor is responsible for certification of conformity with all specifications including FDA regulations and labeling requirements. All packaging, marking, and labeling must adhere to strict government standards including MIL-STD-2073-1 for preservation, MIL-STD-129 for shipping labels, and MIL-STD-130 for item identification. Units must be marked with the NSN, CAGE code, part number, contract number, preservation method and date, and transaction control number, with commercial preservation denoted as “COMM’L” and military as “M” followed by the method and date. Intermediate and exterior containers require bar codes compliant with DoD logistics standards, and hazardous materials necessitate a Shipper’s Declaration for Dangerous Goods and Safety Data Sheets. Shelf life must include at least 12 months remaining at time of delivery for Type I items, with expiration and manufacture dates clearly marked. Each shipment must include a destination label addressed to DODAAC SV3100, and all documentation must be in English using durable, legible markings. The contract requires electronic submission via the DIBBS portal and prohibits paper solicitations. Contractors must maintain inspection records for three years post-delivery and comply with all applicable federal regulations including the Federal Food, Drug, and Cosmetic Act and 49 CFR for hazardous materials. No socioeconomic set-asides apply,
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

7 days ago

DEADLINE

in 24 days
View Details
NAICS: 325414
Awarded
DIBBS
GLOBULIN SERUM, ANTI-HUMAN
Solicitation # SPE2DS-26-T-307T
GLOBULIN SERUM, ANTI-HUMAN is a medical supply item intended for the detection of human IgG bound to red blood cells, packaged in 10 mL vials with a unit of issue of one vial per VI. The product requires refrigerated storage between 2 to 8 degrees Celsius and must have a non-extendable shelf life of 12 months, with no more than one month elapsed between the date of manufacture and the date of delivery to the government. All labels must include the date of manufacture, expiration or retest date, contract number, and lot number, with shelf-life markings strictly compliant with the latest revision of MMS1C. Packaging and marking must adhere to Medical Marking Standard No. 1, which supersedes MIL-STD-129, and each unit must be sealed in a protective container within commercial shipping packaging suitable for safe delivery by common carrier at the lowest cost to the destination, which is APO, Korea with ZIP code 96260-5479. Delivery is FOB destination, with inspection and acceptance performed at the point of delivery, and the item must be delivered within 84 days after award. The contract falls under the NAICS code 621410 and is administered by the Department of Defense through the Medical Supply Chain MD Surg FSF. All submissions must be made electronically via the DLA Internet Bid Board System with a response deadline of August 10, 2026. Payment processing is managed through Wide Area WorkFlow (WAWF), requiring electronic invoicing with an Invoice and Receiving Report for fixed-price line items. The item is governed by a series of FAR and DFARS clauses including safeguards for covered defense information, cybersecurity requirements per NIST SP 800-171, restrictions on hazardous materials, export controls, whistleblower protections, and prohibitions on certain telecommunications equipment. The contractor must comply with hazardous material labeling standards, provide Safety Data Sheets if applicable, and ensure no covered defense telecommunications equipment is used unless exempted. The total estimated contract value is $5,996.00 across multiple line items, all identified by NSN 6550-01-242-2234. Offerors must provide a Unique Entity Identifier and CAGE code and certify their size status, including any socioeconomic designations, with affirmative responses triggering additional disclosures under the covered defense telecommunications clause.
Defense Logistics Agency

POSTED

8 days ago

DEADLINE

N/A
View Details
NAICS: 325414
Federal
Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)
Solicitation # 12639527R0001
Solicitation 12639527R0001 is a request for proposals issued by the USDA Animal and Plant Health Inspection Service (APHIS) for an Indefinite Delivery Indefinite Quantity (IDIQ) contract. The requirement covers the purchase, storage, and production of Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC), the conversion of Government-owned VAC into usable finished vaccines, and the direct purchase of finished vaccines. The contract has a ceiling price of 800 million dollars and a long-term performance horizon, featuring five one-year ordering periods starting approximately December 1, 2026, with conversion and delivery of finished vaccines extending through November 30, 2044. The scope of work requires the contractor to produce VAC capable of yielding at least 1.0 million doses and maintain these materials on their premises under strict quality control and temperature standards. Because live FMDV is a Tier 1 Select Agent, the contractor must hold a select agent authorization issued by CDC/APHIS. Finished vaccines must be packaged to maintain temperatures between 2 to 8 degrees Celsius for 24 hours and include electronic temperature monitors. Award will be based on the most advantageous offer considering technical capability, past performance from the last five years, and fair and reasonable pricing. Proposals must be submitted electronically to Stephen Tees by November 10, 2026, at 1700 CT, organized into four separate volumes.
Mrpbs Minneapolis Mn

POSTED

13 days ago

DEADLINE

in 28 days
View Details
NAICS: 325414
Awarded
Federal
6505--Blood Contract - Madison POP: 10/1/26 - 9/30/31
Solicitation # 36C25226Q0606
The Department of Veterans Affairs, through Network Contract Office 12 in Milwaukee, Wisconsin, is seeking qualified contractors to supply blood and blood products under an indefinite-delivery indefinite-quantity (IDIQ) firm-fixed-price contract with a performance period from October 1, 2026, through September 30, 2031. The solicitation, numbered 36C25226Q0606, issued on July 22, 2026, with responses due by August 21, 2026, requires contractors to provide comprehensive transfusion services across multiple VA medical centers including Milwaukee, Tomah, Jesse Brown, Edward Hines, and the Captain James A. Lovell Federal Health Care Center, with FOB destination terms mandating delivery to these specified locations. Contractual obligations include 24/7 availability of an immunohematology reference laboratory with STAT and routine testing distinctions, strict donor identification and history tracking compliant with FDA protocols, mandatory Hemoglobin S testing for designated units, and adherence to AABB and FDA standards for all testing and processing. Contractors must support facility-specific delivery frequencies, supply biospecimens for training at no additional cost, provide physician consultative services and staff educational programs, and submit historical antigen typing data upon request. Price adjustments for new FDA-mandated tests require 30-day advance notice with justification. The contract prohibits racially discriminatory DEI activities and mandates compliance with multiple FAR clauses including contractor ethics, whistleblower protections, subcontractor restrictions, and affirmative action for veterans. Payment for services must be processed electronically via the Tungsten Network in accordance with FAR 52.232-72, disallowing fax, email, or scanned invoicing. Contractors must register in SAM.gov and maintain current certifications, with evaluations based solely on a best-value trade-off analysis weighing technical capability against price without fixed weightings or LPTA methodology. The government may select a higher-priced offer if it demonstrates superior technical merit or added benefit. Performance locations are diverse and geographically dispersed across Wisconsin and Illinois, requiring robust logistical capability. No specific packaging or marking specifications are outlined, and no detailed scope of work or technical specifications for blood components are provided in the available documentation, placing responsibility on offerors to define and justify their approach. The contracting officer, Teresa Beers, serves as the primary point of contact, while technical oversight will be handled by newly assigned CORs upon award. The absence of defined evaluation sub-factors, key personnel
252-NETWORK Contract Office 12 (36C252)

POSTED

14 days ago

DEADLINE

N/A
View Details

Win Contracts in Biological Product (except Diagnostic) Manufacturing

Get AI-powered intelligence on NAICS 325414 procurement

Real-time contract opportunities for NAICS 325414 (Biological Product (except Diagnostic) Manufacturing)

AI-powered matching based on your business capabilities and past performance

Competitive analysis of contractors winning awards in this industry

Automated alerts when new opportunities are posted

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS